
    
      1. To explore the non-inferiority of a cfDNA amplicon-based liquid biopsy technology vs.
           standard of care tissue biopsy-based NGS in detecting guideline- recommended biomarkers
           in patients with metastatic non-squamous Non-small Cell Lung Cancer (NSCLC), amongst
           other endpoints.

        2. Condition or disease: NSCLC

        3. Intervention/treatment: Observational
    
  